The Boldt scandal still in need of action: the example of colloids 10 years after initial suspicion of fraud

  • Christian J. Wiedermann
  • Michael Joannidis
What's New in Intensive Care


Compliance with ethical standards

Conflicts of interest

CJW has received lecture fees and/or travel cost reimbursements from the Plasma Protein Therapeutics Association, Kedrion, CSL Behring, Grifols and Baxter, and remuneration for consulting from CSL Behring, Grifols, and Daiichi Sankyo. MJ has received fees for lectures and/or consulting from Baxter, CSL Behring, Fresenius and Astute Medical, and research grand support from Fresenius.

Supplementary material

134_2018_5289_MOESM1_ESM.docx (93 kb)
Supplementary material 1 (DOCX 92 kb)


  1. 1.
    Boldt J, Suttner S, Brosch C et al (2009) Cardiopulmonary bypass priming using a high dose of a balanced hydroxyethyl starch versus an albumin-based priming strategy. Anesth Analg 109:1752–1762. CrossRefPubMedGoogle Scholar
  2. 2.
    Klinikum Ludwigshafen (2010) Untersuchungsbericht der Kommission für die Pressekonferenz am 29. November 2010. Accessed 9 Jun 2018
  3. 3.
    Shafer SL (2010) Notice of retraction. Anesth Analg 111:1567. CrossRefPubMedGoogle Scholar
  4. 4.
    Rasmussen LS, Yentis SM, Van Aken H et al (2011) Editors-in-chief statement regarding published clinical trials conducted without IRB approval by Joachim Boldt. Minerva Anesthesiol 77:562–563Google Scholar
  5. 5.
    Boldt J, Brosch C, Ducke M et al (2007) Influence of volume therapy with a modern hydroxyethylstarch preparation on kidney function in cardiac surgery patients with compromised renal function: a comparison with human albumin. Crit Care Med 35:2740–2746CrossRefPubMedGoogle Scholar
  6. 6.
    Boldt J, Brosch Ch, Röhm K et al (2008) Is albumin administration in hypoalbuminemic elderly cardiac surgery patients of benefit with regard to inflammation, endothelial activation, and long-term kidney function? Anesth Analg 107:1496–1503. CrossRefPubMedGoogle Scholar
  7. 7.
    Carlisle J, Pace N, Cracknell J et al (2013) What should the Cochrane Collaboration do about research that is, or might be, fraudulent? Accessed 9 Jun 2018
  8. 8.
    Ioannidis JP, Trikalinos TA, Zintzaras E (2006) Extreme between-study homogeneity in meta-analyses could offer useful insights. J Clin Epidemiol 59:1023–1032CrossRefPubMedGoogle Scholar
  9. 9.
    Wiedermann CJ (2016) Ethical publishing in intensive care medicine: a narrative review. World J Crit Care Med 5:171–179. CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Chaudry IH, Lang CH (2015) Expression of concern. Shock 43:620. CrossRefPubMedGoogle Scholar
  11. 11.
    Palus S (2015) Three more retractions for former record-holder Boldt, maybe more to come. Accessed 9 Jun 2018
  12. 12.
    Zarychanski R, Abou-Setta AM, Turgeon AF et al (2013) Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA 309:678–688. CrossRefPubMedGoogle Scholar
  13. 13.
    Hackenbroch V (2011) Arzneimittel: Wissenschaftliches Vakuum. Accessed 9 Jun 2018
  14. 14.
    Wiedermann CJ (2018) Inaction over retractions of identified fraudulent publications: ongoing weakness in the system of scientific self-correction. Acc Res 25:239–253. CrossRefGoogle Scholar
  15. 15.
    Carlisle JB (2017) Data fabrication and other reasons for non-random sampling in 5087 randomised, controlled trials in anaesthetic and general medical journals. Anaesthesia 72:944–952. CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature and ESICM 2018

Authors and Affiliations

  • Christian J. Wiedermann
    • 1
  • Michael Joannidis
    • 2
  1. 1.UMIT-University of Health Sciences, Medical Informatics and TechnologyHall in TyrolAustria
  2. 2.Division of Medical Intensive Care and Emergency Medicine, Department of Internal Medicine IMedical University of InnsbruckInnsbruckAustria

Personalised recommendations